There are currently 123 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are California, Florida, Texas and New York.
Mechanisms of Rumination Change in Adolescent Depression
Recruiting
This study will evaluate whether a newer treatment, rumination-focused cognitive behavioral treatment, which includes mindfulness and can be used to reduce ruminative habits, change ways in which key brain regions interact with each other (e.g.., often called connectivity), and whether these changes in habits and brain connectivity can reduce the risk for recurrence of depression in the next two years.
Gender:
ALL
Ages:
Between 14 years and 17 years
Trial Updated:
06/25/2024
Locations: Nationwide Children's Hospital, Columbus, Ohio +2 locations
Conditions: Major Depressive Disorder, Mood Disorders
Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study
Recruiting
The purpose of this study is to assess the feasibility of combining IV ketamine, a rapid acting antidepressant, with a course of Mindfulness-Based Cognitive Therapy (MBCT), for the initial and maintenance treatment of depression.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/10/2023
Locations: Harding Hospital, Columbus, Ohio
Conditions: Major Depressive Disorder
Using mHealth to Improve Adherence and Reduce Blood Pressure in Individuals With Hypertension and Mood Disorders
Recruiting
This proposed 2-stage randomized controlled trial (RCT) will evaluate a personalized patient-centered adherence intervention iTAB-CV + Self-Monitoring (iTAB-CV + SM) vs. Self-Monitoring (SM) alone in poorly adherent hypertensive persons with BD or MDD. This practical, technology-facilitated intervention has potential to improve adherence to antihypertensive medication and reduce SBP among high-risk individuals. The intervention is suitable for primary care or mental health settings and has poten... Read More
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
05/22/2025
Locations: Case Western Reserve University, Cleveland, Ohio
Conditions: Bipolar Disorder, Non-Adherence, Medication, Hypertension, Major Depressive Disorder
Evaluating tDCS Brain-stimulation in Depression Using MRI
Recruiting
Patients, physicians, and those who fund depression research are keenly interested in depression treatments that do not involve taking medications. One promising candidate treatment is transcranial direct current stimulation (tDCS), a low-cost technique that involves placing electrodes on specific scalp locations and using a 9-volt battery to cause a small amount of electricity to pass through parts of the brain. Depending on the direction of electrical flow, tDCS can make brain cells (neurons)... Read More
Gender:
ALL
Ages:
Between 20 years and 55 years
Trial Updated:
05/29/2025
Locations: University of California Los Angeles (UCLA), Los Angeles, California
Conditions: Major Depressive Disorder
Natural History of Depression, Bipolar Disorder and Suicide Risk
Recruiting
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medica... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents, Analgesics, Peripheral Nervous System Agents, Physiological Effects of Drugs, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Central Nervous System Depressants, Excitatory Amino Acid Antagonists, Excitatory Amino Acid Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Ketamine, Depression, Unipolar, Depressive Symptoms, Treatment Resistant Depression, Major Depressive Disorder, Depression, Bipolar
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Recruiting
Study Description: This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG). Patients will be studied over one year, before and after receiving either one of two standard-of-care treatments: cognitive behavioral therapy (CBT) or fluoxetine, a serotonin reuptake inhibitor (SSRI). Healthy comparisons will be s... Read More
Gender:
ALL
Ages:
Between 8 years and 65 years
Trial Updated:
05/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Major Depressive Disorder, Anxiety Disorders
Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation
Recruiting
The purpose of this study is to gather information regarding the use of a new type of transcranial magnetic stimulation (TMS) called theta burst stimulation (TBS) for suicidal ideation in adolescents with Major Depressive Disorder (MDD). The investigators hope to learn if this TMS treatment improves suicidal ideation over 10 days and clinical outcomes over 1 year of follow-up.
Gender:
ALL
Ages:
Between 12 years and 18 years
Trial Updated:
05/21/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Suicidal Ideation, Major Depressive Disorder
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
Recruiting
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2025
Locations: Reverie Mind, LLC, Chandler, Arizona +66 locations
Conditions: Major Depressive Disorder
Open Label Optimization Study
Recruiting
The goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder The primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I at the end of the treatment Participants will receive 10 treatments per day for 5 days (M-F) of SAINT®
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: BrainHealth Solutions, Costa Mesa, California +6 locations
Conditions: Major Depressive Disorder
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
Recruiting
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
05/19/2025
Locations: Preferred Research Partner, Fayetteville, Arkansas +25 locations
Conditions: Major Depressive Disorder
Defining Neurobiological Links Between Substance Use and Mental Illness
Recruiting
Background: Nicotine dependence leads to about 480,000 deaths every year in the United States. People with major depressive disorder (MDD) are twice as likely to use nicotine compared to the general population. They have greater withdrawal symptoms and are more likely to relapse after quitting compared with smokers without MDD. More research is needed on how nicotine affects brain function in those with MDD. Objective: To understand how nicotine affects symptoms of depression and related brai... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/17/2025
Locations: National Institute on Drug Abuse, Baltimore, Maryland
Conditions: Major Depressive Disorder, Substance Use Disorder, Normal Physiology
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Recruiting
This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and mee... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/14/2025
Locations: Neumora Investigator Site, Cerritos, California +67 locations
Conditions: Major Depressive Disorder